A firm can face a situation in which it needs to engage a third party, and this may be encouraged or required in order to address a health-agency regulatory citation.  For example, consider the following language from an FDA Warning Letter (WL):

“Based upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.  Your use of a consultant does not relieve your firm’s obligation to comply with CGMP.”

When a firm receives a WL from the FDA and the Agency references significant cGMP violations, the finished product generated from that firm is considered adulterated.  Due to the significance of the Form 483 violations along with the content of the 483 response, the Agency deemed that a Warning Letter was needed; with the above wording within the WL, the Agency is likely questioning the ability of the firm’s Quality Unit to successfully remediate the findings without the input of a third-party consultant.

With this all in mind, it should be noted that responding to a Form 483 is a critical activity that can have far-reaching considerations, including whether a WL will be issued.  The recently issued draft guidance titled Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection (March 2026) states:

“If a written FDA 483 response is submitted, it may be the primary or a key component in FDA’s review when evaluating whether subsequent Agency action is warranted.  FDA 483 responses should be as accurate, clear, concise, and well-organized as necessary to convey an establishment’s position.”

As such, the engagement of a third party could have significant benefit as it relates to ensuring that the response considers the content of this guidance and includes the necessary and appropriate immediate actions to contain risk (associated with the observations) along with holistic impact assessments and interim and long-term CAPAs.  The March 2026 draft guidance also states:

“There may be situations where a consultant is useful for additional insight to understand and assess inspectional observations and to develop an appropriate CAPA plan.  For example, FDA recommends establishments engage a CGMP consultant when observations involve data integrity findings.”

Such a third-party consulting engagement for a CAPA plan is also applicable to the response and remediation of a Warning Letter.  An important consideration for a CAPA plan is the scope of impact.  It should not be assumed that the scope is limited to the site that received the citation.  The 2026 draft guidance states:

“FDA expects that an establishment’s management reviews the FDA 483 at the facility level and, if applicable, at the corporate level.”

A critical component of a CAPA plan is addressing why the observations were not self-identified by the firm’s quality unit.  As per the March 2026 draft guidance:

“During an investigation, it may also be valuable for an establishment to determine why the issues leading to the observation were not previously identified by the quality unit or corrected by the establishment’s management before the FDA inspection.  Further, the establishment should consider how improvements to the quality system, personnel management, and overall quality culture may improve organizational performance.”

This is where a third-party consultant can add considerable value.  Most often, the objective is an independent perspective of why such observations were issued by the Agency, whereby the true root cause(s) of such observations are considered when constructing a response, which will feed into a robust CAPA plan (including actions identified to support ongoing operations).

In the spirit of “an ounce of prevention is worth a pound of cure,” engaging a third-party consultant as part of the 483-response team could also have benefit as it relates to the “subsequent Agency action” that is referenced in the FDA guidance document, up to (depending upon the severity of the observations) heading off a potential WL.

Further, it is not just dealing with regulatory responses; engaging a consultant earlier in any process can provide significant savings.  For example, having a third party review a design plan, major qualification/commissioning protocols, strategy documents, etc. may mitigate the risk of a firm needing to do costly “rework” for the impacted system while needing to initiate investigations, FARs/recalls, etc.

If you have any questions related to engaging the services of a third-party consultant, please reach out to Lachman at LCS@lachmanconsultants.com.